𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Features of immune senescence in liver transplant recipients with established grafts

✍ Scribed by William Gelson; Matthew Hoare; Sarah Vowler; Arun Shankar; Paul Gibbs; Arne N. Akbar; Graeme J. M. Alexander


Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
206 KB
Volume
16
Category
Article
ISSN
1527-6465

No coin nor oath required. For personal study only.

✦ Synopsis


Immune senescence is the normal process whereby the human immune system ages, but becomes less effective. We investigated whether liver transplant recipients have features of immune senescence. Lymphocytes from 97 liver transplant recipients with established grafts and 41 age-matched and sex-matched controls were subjected to an 8-color flow cytometry assay that measured expression of killer cell lectin-like receptor subfamily G member 1, cluster of differentiation 127 (CD127), CD45RO, CD27, CD28, CD4, CD8, and CD57. Lymphocyte telomere length was assessed by flow-fluorescence in situ hybridization. Cases were compared with controls for each marker of immune senescence using a Mann-Whitney U test. For liver transplant recipients, linear regression analyses identified associations between markers of immune senescence and clinical or demographic characteristics. Lymphocytes from liver transplant recipients expressed more phenotypic markers of maturity than did lymphocytes from controls. Lymphocyte telomeres were shorter in liver transplant recipients than in controls. Age, hepatocellular carcinoma at transplantation, and skin malignancy developing after transplantation were associated independently with shortened lymphocyte telomeres. Increasing age and previous cytomegalovirus infection were associated independently with phenotypic markers of lymphocyte maturity. Thus, lymphocytes from liver transplant recipients are older ''biologically'' than lymphocytes from age-matched and sex-matched controls. Hepatocellular carcinoma at transplantation, subsequent skin malignancy, and previous cytomegalovirus infection are associated with lymphocyte senescence in liver transplant recipients.


πŸ“œ SIMILAR VOLUMES


Early immunological monitoring after ped
✍ JΓ©rΓ©mie Gras; GrΓ©goire WieΓ«rs; Jean-Luc Vaerman; Dinh Quang Truong; Etienne Soka πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 153 KB

Cytokine deviation may be a factor contributing to graft acceptance. We analyze, in the context of liver transplantation, circulating cytokine levels and their mRNA precursors in liver biopsy samples to study a putative correlation with early immunologic outcome. Forty primary pediatric liver recipi

ImmuKnow: A new parameter in immune moni
✍ Moshe Israeli; Tirza Klein; Benjamin Sredni; Yaron Avitzur; Eitan Mor; Nathan Ba πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 298 KB πŸ‘ 1 views

Lifelong immunosuppression is mandatory for optimal graft and patient survival following liver transplantation. Nevertheless, graft rejection or numerous adverse events associated with overimmunosuppression or underimmunosuppression cannot be completely avoided. The ImmuKnow assay measures cell-medi

Hepatitis A antibodies in liver transpla
✍ Mehmet Arslan; Russell H. Wiesner; John J. Poterucha; B.John Gross Jr; Nizar N. πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 60 KB πŸ‘ 1 views

Liver transplant recipients frequently have chronic liver diseases and should be considered for vaccination against hepatitis A virus (HAV). However, persistence of protective antibodies after orthotopic liver transplantation (OLT) has not been shown in this population, which may have implications f

Safety and effectiveness of ezetimibe in
✍ Fawaz Almutairi; Theresa C. Peterson; Michele Molinari; Mark J. Walsh; Ian Alway πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 118 KB

Hypercholesterolemia is a common problem among transplant recipients. Despite package-insert warnings about the potential side effects of the use of statins in patients with chronic liver disease, they are often prescribed for liver transplant recipients. Unlike statins, ezetimibe acts through inhib

Hepatitis E virus infection as a cause o
✍ Sven Pischke; Pothakamuri V. Suneetha; Christine Baechlein; Hannelore Barg-Hock; πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 256 KB πŸ‘ 2 views

Hepatitis E virus (HEV) infection induces self-limiting liver disease in immunocompetent individuals. Cases of chronic hepatitis E have recently been identified in organ transplant recipients. We questioned if chronic hepatitis E plays a role in graft hepatitis after liver transplantation in a low e